IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Heartland Bank & Trust Co

Heartland Bank & Trust Co cut its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 3.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,433 shares of the company’s stock after selling 46 shares during the quarter. Heartland Bank & Trust Co’s holdings in IDEXX Laboratories were worth $795,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Moneta Group Investment Advisors LLC raised its stake in shares of IDEXX Laboratories by 121,647.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock worth $3,038,192,000 after buying an additional 7,441,162 shares during the period. Norges Bank acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $336,416,000. Morgan Stanley raised its stake in shares of IDEXX Laboratories by 36.0% during the 4th quarter. Morgan Stanley now owns 986,232 shares of the company’s stock worth $402,344,000 after buying an additional 260,926 shares during the period. Alliancebernstein L.P. raised its stake in shares of IDEXX Laboratories by 6.4% during the 2nd quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company’s stock worth $1,804,428,000 after buying an additional 214,529 shares during the period. Finally, Winslow Capital Management LLC raised its stake in shares of IDEXX Laboratories by 24.9% during the 3rd quarter. Winslow Capital Management LLC now owns 689,873 shares of the company’s stock worth $301,661,000 after buying an additional 137,621 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at IDEXX Laboratories

In other news, SVP George Fennell sold 8,198 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares in the company, valued at approximately $3,851,815.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, SVP George Fennell sold 8,198 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares in the company, valued at approximately $3,851,815.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Brian P. Mckeon sold 23,326 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the transaction, the chief financial officer now owns 29,718 shares of the company’s stock, valued at $16,939,557.18. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,524 shares of company stock worth $24,871,960. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Trading Up 1.4 %

NASDAQ:IDXX traded up $7.44 during trading hours on Wednesday, hitting $529.11. The company had a trading volume of 55,415 shares, compared to its average volume of 419,679. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.42. The company has a 50-day moving average of $548.68 and a 200 day moving average of $504.25. The company has a market cap of $43.94 billion, a P/E ratio of 52.29, a P/E/G ratio of 2.92 and a beta of 1.26. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last issued its earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.20. The company had revenue of $901.60 million during the quarter, compared to analysts’ expectations of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the business earned $2.05 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. BNP Paribas assumed coverage on IDEXX Laboratories in a research note on Thursday, December 7th. They set an “outperform” rating and a $602.00 target price for the company. The Goldman Sachs Group boosted their price target on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Barclays boosted their price target on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Wednesday, December 20th. Finally, JPMorgan Chase & Co. boosted their price target on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $591.50.

Read Our Latest Analysis on IDEXX Laboratories

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Featured Articles

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.